LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession

Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics

“Our strong third-quarter results demonstrate continued progress in the commercialization of VIZZ, with product sales growth of 50%, increasing patient adoption and encouraging refill rates. We view these as promising indicators of our positive trajectory in this emerging market.”

Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics

“We are focusing our commercial organization and investment on initiatives we believe will most effectively increase consumer awareness, access and adoption, while improving capital efficiency and supporting VIZZ’s continued growth. I am encouraged by the growing third-quarter consumer demand that is continuing into the fourth quarter, and excited about the opportunities ahead for LENZ.”

Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics

“After nearly six years leading LENZ and more than 25 years in the biotechnology industry, I have decided to transition from my role as CEO effective December 1, 2026, to devote more time to other passions. I am very proud of the team we have built, the culture we have created and the successes we have achieved together. I am deeply grateful to our employees, the Board and our shareholders for their support. I believe as strongly as ever in LENZ’s future and have full confidence in Dan’s ability to lead the company. Dan and I will work closely to ensure a smooth handover, and I look forward to continuing to support him and the Board as a strategic advisor following the CEO transition.”

Jeff George, Chairman of the Board of Directors of LENZ Therapeutics

“We are deeply grateful to Eef for his leadership in building LENZ from our Series A into a well-capitalized public company and advancing VIZZ through clinical development, FDA approval and commercial launch. We wish him all the best for the future,”

Jeff George, Chairman of the Board of Directors of LENZ Therapeutics

“Dan brings a deep understanding of LENZ and our operating priorities and has our full confidence to lead the company as Interim CEO, with continued support from Eef and the Board through the transition. We are confident in the opportunity ahead for VIZZ and in our team’s ability to execute on the more focused commercial strategy announced today.”

Dan Chevallard, Chief Financial Officer and incoming Interim Chief Executive Officer of LENZ Therapeutics

“I am grateful to Eef for his leadership and contributions to LENZ and look forward to building on the solid foundation we have established. I am honored to lead LENZ through this next phase. Our priorities are clear: drive continued increases in consumer awareness, access and adoption of VIZZ and deploy our resources with discipline. I firmly believe in VIZZ’s potential and our team’s ability to deliver on these priorities.”